Traditional Tibetan medicine (TTM) plays an important role in the health care system of China. Little is known about the current evidence of TTM's clinical research in China. Randomized controlled trials (RCTs) of TTM therapies conducted in China were searched in PubMed, Cochrane Library, two major Chinese electronic databases, and two Tibetan medical journals from their inception to June 2014. Qualitative analysis and reporting quality assessment were performed. The protocol was registered in PROSPERO (No: CRD42013006881). A total of 227 RCTs involving 29,179 participants were included. They were heterogeneous in terms of study size, sites, treated conditions, interventions, measured outcomes, and quality. 103 diseases or symptoms were reported in the included trials. TTM interventions used in the RCTs consisted of drug treatments and non-drug treatments including bloodletting and moxibustion, in which Tibetan patent medications for oral use were tested in 175 studies and for external use in 47 studies. 93.8% (213/227) of the trials reported superior effect of TTM over control interventions. Only 7.9% (18/227) of the trials described details of random sequence generation, 3.5% (8/227) described details of blind. Clinical research in TTM in China covers whole medical systems. Data from RCTs showed that TTM might have potential benefit for the management of many diseases. Studies on definitive health outcomes could be systematically reviewed in order to provide more information on TTM's efficacy. More efforts should be made to improve the quality of RCTs in China and support TTM's further clinical applications.